This placebo-controlled, double-blind, randomized, Phase 3 study is being conducted in adult participants with high-risk atherosclerotic cardiovascular disease (ASCVD) who are not adequately controlled by their maximally tolerated lipid-modifying therapy, to assess the impact of the obicetrapib 10 mg + ezetimibe 10 mg FDC daily on coronary plaque and inflammation characteristics, evaluated using cardiovascular computed tomography angiography (CCTA).

Inclusion Criteria:

• Fasting serum LDL-C ≥70 mg/dL (≥1.81 mmol/L)
• Evaluable non-calcified plaque of at least 75 mm3 in the major epicardial coronary arteries
• BMI 18-40, inclusive
• Max tolerated lipid modifying therapy
• Estimated glomerular filtration rate ≥40 mL/min/1.73 m2

Exclusion Criteria:

• HbA1c ≥10.0% (≥0.100 hemoglobin fraction) or a fasting glucose ≥270 mg/dL (≥15.0 mmol/L) at Screening
• Contraindications for CCTA
• History of coronary artery bypass graft
• Active liver disease

Double blind set-up; post randomization LDL values are not provided to sites (alert triggers are programmed for urgent follow-up)